CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC …
About CRB-701 CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug …
CRB-701 (SYS6002) A Next Generation Nectin-4 …
Jan 26, 2024 · CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is …
Corbus Presents CRB-701 Phase 1 Data With Promising Efficacy In ...
22 hours ago · CRB-701 demonstrated a comparable pharmacokinetic or PK profile to the China study, with a longer ADC half-life and lower free-MMAE exposure compared to enfortumab …
CRB-701 (SYS6002) A Next Generation Nectin-4 …
1 day ago · CRB-701 was well tolerated with majority of treatment emergent adverse events being grade 1 or 2 in both studies. Notably few cases of peripheral neuropathy or skin rash have been reported to date ...
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 …
4 days ago · CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio …
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 …
Jan 9, 2025 · CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio …
- People also ask
Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation …
Jan 29, 2024 · SYS6002 (CRB-701) is a next generation Nectin-4 ADC that makes use of third-generation conjugation technology designed to overcome dose-limiting toxicities observed with …
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to …
Clinical update related to the first-in-human trial of SYS6002 (CRB …
May 29, 2024 · SYS6002 (CRB-701) exhibited a longer ADC half-life and lower free-MMAE exposures relative to EV at comparable dose levels. Conclusions: SYS6002 (CRB-701) …
Abstract C121: Development of CRB-701 (SYS6002): A …
Dec 1, 2023 · CRB-701 (SYS6002) is a clinical stage, next generation ADC targeting Nectin-4 wherein two monomethyl auristatin E (MMAE) moieties are site-specifically conjugated to a novel Nectin-4 targeting IgG1 antibody via a …
- Some results have been removed
